Fig. 3.

Mice were highly resistant to EAE onset via shifting monocyte subsets towards Ly6C^low monocytes in response to the MDP treatment. (a) Representative timeline of the entire protocol, including EAE inducing, MDP administrations, and FACS analysis in mice treated with vehicle (n = 7) or MDP (n = 7). (b) Clinical scores of mice treated with vehicle or MDP were determined daily after immunization. Data are expressed as the means ± SEM; ****P < 0.0001, ***P = 0.0008, two-way ANOVA followed by Tukey’s multiple comparisons test. (c) The variation of body weight has been expressed compared to the day of EAE induction (day 0) as mean ± SEM; ****P < 0.0001, ***P = 0.0001, two-way ANOVA followed by Tukey’s multiple comparisons test. (d) Percentage of disease incidence in mice treated with vehicle or MDP. Data are expressed as the means ± SEM; *P = 0.02, log–rank (Mantel–Cox) test. (e) and (f) Absolute count of blood Ly6C^hi and Ly6C^low monocytes respectively following treatment with vehicle or MDP in EAE mice as measured by flow cytometry 1 week after MDP injections (9 days after immunization). Data are expressed as the means ± SEM; **P < 0.05 versus EAE–vehicle, ^###P < 0.0001 versus EAE–vehicle, Student’s t test